Cerus (NASDAQ:CERS) is a biomedical products company engaged in the development and provision of innovative blood transfusion solutions. Their main focus is on enhancing blood safety through their Intercept Blood System, designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites present in donated blood. The company is solely listed on the NASDAQ stock exchange under the ticker symbol CERS. Cerus is dedicated to protecting public health and improving patient care by addressing critical needs in blood safety. Their objectives include expanding the adoption of the Intercept Blood System globally, investing in research and development to extend their product offerings, and exploring new opportunities to leverage their pathogen inactivation technology across different medical applications.